Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS [Phase 1, Phase 2]

View source ↗

Summary

A single-participant Phase 1/2 trial is evaluating a personalized antisense oligonucleotide therapy for CHCHD10-related amyotrophic lateral sclerosis. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Personalized antisense oligonucleotide therapy for CHCHD10-associated ALS

Snippet

Sponsor: n-Lorem Foundation | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING